A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Asia Pacific Patients With Locally Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene

Trial Profile

A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Asia Pacific Patients With Locally Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms AURA17
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 Sep 2017 Results of a prespecified subgroup analysis (n=59) assessing efficacy of osimertinib in CNS metastases in Asian-Pacific patients with T790M-positive advanced NSCLC, presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Sep 2017 Updated results (n=171; as of 4 Nov 2016) presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Results of methods of confirmation of presence of T790M in patients from AURA17 study presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top